Enantiomerically pure hydroxylated xanthine compounds to treat autoimmune diabetes
US5739138A · kind A · utility
12Cited by
12References
2Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 1, 1995 |
| Grant date | Apr 14, 1998 |
| Priority date | — |
| Expiry date | Jun 1, 2015 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02P20/582
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
There is disclosed compounds and pharmaceutical compositions that are a resolved R or S (preferably R) enantiomer of an .omega.-1 alcohol of a straight chain alkyl (C.sub.5-8) substituted at the 1-position of 3,7-disubstituted xanthine. The inventive compounds are effective in modulating cellular response to external or in situ primary stimuli, as well as to specific modes of administration of such compounds in effective amounts.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.